Pubblicazioni Meet-URO
Prognostic value of type of prior TKI in pretreated Metastatic Renal Cell Carcinoma patients receiving Nivolumab
Autore: Sara Elena Rebuzzi | Anno: 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study
Autore: Carlo Messina | Anno: 2024
Neutrophil-to-eosinophil ratio predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma enrolled in the MALVA study (Meet-URO 25).
Autore: Elisabetta Gambale | Anno: 2024
Analyses of tumor microenvironment in advanced renal cell carcinoma patients receiving immunotherapy (Meet-URO 18 study)
Autore: Sara Elena Rebuzzi | Anno: 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
Autore: Veronica Murianni | Anno: 2024
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial
Autore: Massimo Di Maio | Anno: 2023
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
Autore: Sara Elena Rebuzzi | Anno: 2023
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
Autore: Sara Elena Rebuzzi | Anno: 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
Autore: Sara Elena Rebuzzi | Anno: 2022
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
Autore: Sara Elena Rebuzzi | Anno: 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
Autore: Sara Elena Rebuzzi | Anno: 2022
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
Autore: Pasquale Rescigno | Anno: 2022
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)
Autore: Melissa Bersanelli | Anno: 2022
The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
Autore: Giuseppe Banna | Anno: 2022
Bone metastases from urothelial carcinoma. The dark side of the moon
Autore: Marco Stellato | Anno: 2021
Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
Autore: Marco Maruzzo | Anno: 2021
Clinical outcomes of patients with metastatic urothelial carcinoma after progression to immune checkpoint inhibitors: a retrospective analysis by the Meet-Uro group (MEETURO-1 study)
Autore: Melissa Bersanelli | Anno: 2021
Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
Autore: Marco Stellato | Anno: 2023
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
Autore: Alessia Mennitto | Anno: 2021
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
Autore: Giuseppe Fornarini, Sara Elena Rebuzzi | Anno: 2023
Safety and efficacy of Tivozanib in first-line mRCC: a multicenter compassionate use study (Meet-URO 16)
Autore: Umberto Basso | Anno: 2021
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: development of a novel prognostic score (Meet-URO 15 study)
Autore: Giuseppe Fornarini, Sara Elena Rebuzzi | Anno: 2021
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
Autore: Marco Stellato | Anno: 2021
Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology (I-O). A real-world study on behalf of Meet-URO group (MeetUro-7b)
Autore: Marco Stellato | Anno: 2021
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). A Meet-URO Group Real World Study (Meet-Uro 7)
Autore: Daniele Santini, Marco Stellato | Anno: 2021
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO network
Autore: Giuseppe Banna | Anno: 2023
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Autore: Giuseppe Procopio | Anno: 2023
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)
Autore: Giuseppe Procopio | Anno: 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study
Autore: Daniele Raggi | Anno: 2022